Skip to content

NOVEL APPROACH TO PREVENT SARCOPENIA USING A COMBINATION OF EICOSAPENTAENOIC ACID (EPA) AND BRANCH CHAIN AMINO ACIDS (BCAA): A PILOT STUDY IN ELDERLY PEOPLE WITH INADEQUATE PROTEIN INTAKE

A PILOT STUDY IN ELDERLY PEOPLE WITH INADEQUATE PROTEIN INTAKE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230116005
Enrollment
84
Registered
2023-01-16
Start date
2021-07-26
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly that are at risk of sarcopenia with inadequate protein intake EPA, BCAA sarcopenia muscle nutrition

Interventions

1. Control Nutrition drink 500 kcal,Nutrition drink 500 kcal + 2.2 g of EPA ,Nutrition drink 500 kcal + 2.2 g of EPA + 5 g BCAA containing 2:1:1 (Leu: Iso: Val) ,Nutrition drink 500 kcal + 2.2 g
Control,2. Complete nutrition fortified with 2.2 g of EPA ,3. Complete nutrition fortified with 2.2 g of EPA and 5 g BCAA 2:1:1 (Leu: Iso: Val),4. Complete nutrition fortified with 2.2 g of EPA and 5

Sponsors

Thailand Science Research and Innovation (TSRI)
Lead Sponsor
Thai Otsuka Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male and female at age 18 and above for sensory test (n=80) for sensory of fortified nutrition drink 2. Elderly male and female 60-90 years old (n=84) for observation of nutrition intake 3. Elderly must have inadequate protein intake (consuming less than 0.8g/ kg body weight per day for at least 7 consecutive days or consuming less than 0.8g/ kg body weight per day for at least 14 consecutive days 4. No systemic diseases or having stable and well-controlled diabetes, hypertension, or dyslipidemia 5. Normal liver and renal function (ALT less than 60 IU/L) and eGFR (more than 60 ml/min)

Exclusion criteria

Exclusion criteria: 1. Individuals who could not respond via writing or communicate with researchers were excluded. All panelists with allergic to milk and soy were not involved in the product evaluation. The sickness that consequences to incapability to smell or taste has to be eliminated. 2. Unable to communicate via reading and writing 3. Participants with cancer, liver disease, renal disease at stage 3 to 5, and Alzheimer's. 4. Participants with symptoms of malabsorption such as short bowel syndrome, alcoholism, inflammatory bowel disease (IBD), and pancreatitis 5. Individuals with allergies to fish, soybean, peanut, and milk

Design outcomes

Primary

MeasureTime frame
Sensory acceptability one time 5 point hedonic score,Body weight, Body composition (muscle mass, fat mass) Day 0 and 21 BIA, kg, % distribution,Energy and macronutrient intake Day 0 and 21 dietary record and analysis (INMUCAL),Hand grip strength Day 0 and 21 hand dynamometer,Plasma EPA Day 0 and 21 LC-MS/MS,Plasma BCAA Day 0 and 21 LC-MS/MS,Markers of muscle degradation (carnosine, histidine, beta-alanine) Day 0 and 21 LC-MS/MS,Serum IL-6, IL-10 Day 0 and 21 ELISA

Secondary

MeasureTime frame
CBC, glucose, cholesterol, liver function and kidney function Day 0 and 21 routine blood chemistry test

Countries

Thailand

Contacts

Public ContactWatcharapol Khoonin

Institute of Nutrition

watcharapol.k@gmail.com0865912389

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026